Comparative Pharmacology
Head-to-head clinical analysis: MOMETASONE FUROATE versus PULMICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOMETASONE FUROATE versus PULMICORT.
MOMETASONE FUROATE vs PULMICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokines, chemokines, and adhesion molecules involved in inflammation.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway edema and mucus secretion.
Inhaled: 110-880 mcg twice daily; Intranasal: 2 sprays (50 mcg/spray) per nostril once daily; Topical: Apply thin film to affected area once daily.
Inhalation: 200-800 mcg twice daily for maintenance; maximum 1600 mcg/day. Nebulization: 0.5-1 mg twice daily.
None Documented
None Documented
The terminal elimination half-life is approximately 5.8 hours (range 4.5–7.5 hours) following intravenous administration; after intranasal or inhalation use, the effective half-life supporting once-daily dosing is derived from receptor binding and local tissue retention.
The terminal elimination half-life of budesonide is approximately 2.0 to 3.6 hours in adults, with a mean of about 2.8 hours. This short half-life is consistent with its rapid clearance and lack of significant accumulation with once- or twice-daily dosing.
Mometasone furoate is extensively metabolized in the liver; less than 1% of the dose is excreted unchanged in urine. The metabolites are primarily excreted in feces (~74%) via biliary elimination, with renal excretion accounting for approximately 8–10%.
Budesonide is primarily metabolized in the liver via CYP3A4 to inactive metabolites. Approximately 60% of the dose is excreted in urine as metabolites, and 40% in feces. Less than 10% of unchanged drug is excreted renally.
Category A/B
Category C
Topical / Inhaled Corticosteroid
Inhaled Corticosteroid